Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis
Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect h...
Saved in:
Published in | Diabetologia Vol. 42; no. 1; pp. 55 - 59 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Berlin
Springer
01.01.1999
|
Subjects | |
Online Access | Get full text |
ISSN | 0012-186X 1432-0428 |
DOI | 10.1007/s001250051113 |
Cover
Loading…
Abstract | Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells. |
---|---|
AbstractList | Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells.Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells. Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells. |
Author | Hoorens, A. Pipeleers, D. |
Author_xml | – sequence: 1 givenname: A. surname: Hoorens fullname: Hoorens, A. – sequence: 2 givenname: D. surname: Pipeleers fullname: Pipeleers, D. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1737413$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10027579$$D View this record in MEDLINE/PubMed |
BookMark | eNpt0U1P3DAQBmALgWD5OPaKfKh6IjCO4zg5VqgtlRBcQOIWjSdecJvYS-wg7b8nEUtXRZx88DOv9Y4P2a4P3jL2RcC5ANAXEUDkCkAJIeQOW4hC5hkUebXLFvNVJqry4YAdxvgHAKQqyn12ME3mWul6wV5uHIXkPPautXw1hGQpRf409ui5sQk52a6LHB_R-Zg4PdneEXbdOnO-Hcm23FsaQnTxjJsxcR_SFq9T-Ou8_UdxFVZptsdsb4ldtCeb84jd__xxd3mVXd_--n35_TojqXTKNLY52AIMWQNQG2UMkda11KalEkkog6qoS1NJraEUbU2YF3VegSxbWZM8Yt_ecqdmz6ONqeldnBuht2GMTVmrqiiFmuDpBo6mt22zGlyPw7p539QEvm4Axqn_ckBPLm6dlroQcmLyjc07iYNdNuQSJhd8GtB1U94cqZv_vm2ayj5Mbd__zL8Cz7KZgw |
CitedBy_id | crossref_primary_10_1038_sj_bjp_0704156 crossref_primary_10_1111_j_1600_6143_2006_01452_x crossref_primary_10_3727_096368910X515872 crossref_primary_10_2310_6650_2001_33721 crossref_primary_10_1039_B202503E crossref_primary_10_3727_000000004783983602 crossref_primary_10_1016_S1499_2671_07_14011_9 crossref_primary_10_1246_cl_2001_1184 crossref_primary_10_1097_TP_0b013e3181d98af1 crossref_primary_10_1007_s00125_012_2713_z crossref_primary_10_1016_j_abb_2013_03_011 crossref_primary_10_1124_pr_54_3_375 crossref_primary_10_1097_00007890_200201150_00014 crossref_primary_10_2183_pjab_97_022 crossref_primary_10_1251_bpo113 crossref_primary_10_1080_0891693021000010703 crossref_primary_10_1016_j_ejphar_2006_06_016 crossref_primary_10_2337_diabetes_50_3_551 crossref_primary_10_1053_beem_2001_0152 crossref_primary_10_1210_jc_2015_1216 crossref_primary_10_1016_S0006_2952_01_00847_4 crossref_primary_10_1556_JPC_15_2002_6_3 crossref_primary_10_2337_diabetes_51_2007_S462 crossref_primary_10_1097_MPA_0000000000000645 crossref_primary_10_1021_pr500643h crossref_primary_10_1155_2013_905175 crossref_primary_10_1177_096368970000900314 crossref_primary_10_1016_j_mce_2010_02_016 crossref_primary_10_2337_diabetes_50_8_1771 crossref_primary_10_1006_jaut_2001_0507 crossref_primary_10_1016_S0140_6736_04_15786_3 crossref_primary_10_2337_diabetes_50_5_909 crossref_primary_10_1002__SICI_1099_0801_200004_14_2_69__AID_BMC922_3_0_CO_2_N crossref_primary_10_1128_MCB_21_16_5605_5613_2001 crossref_primary_10_1046_j_1365_2265_2001_01398_x crossref_primary_10_1016_S0014_4827_02_00027_7 crossref_primary_10_1152_ajpendo_00320_2003 crossref_primary_10_1021_bm900420f crossref_primary_10_2337_diabetes_52_7_1683 crossref_primary_10_1111_j_1753_4887_2004_tb00059_x crossref_primary_10_1007_s00125_008_0936_9 crossref_primary_10_1016_j_pbb_2011_07_003 crossref_primary_10_3389_fimmu_2021_634797 crossref_primary_10_1080_10915810500434183 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS |
Copyright_xml | – notice: 1999 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1007/s001250051113 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1432-0428 |
EndPage | 59 |
ExternalDocumentID | 10027579 1737413 10_1007_s001250051113 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1CY 1N0 1SB 203 29F 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 4.4 406 408 409 40D 40E 53G 5GY 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AABHQ AACDK AAEWM AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAWCG AAYIU AAYQN AAYTO AAYXX AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFSG ABFTV ABHLI ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSTC ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDYV AFDZB AFFNX AFHIU AFJLC AFKRA AFLOW AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGVAE AGWIL AGWZB AGYKE AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU CITATION COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBLON EBS EIOEI EJD EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z J5H JBSCW JCJTX JZLTJ KDC KOV KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P6G P9S PF0 PHGZM PHGZT PQQKQ PROAC PSQYO PT4 Q2X QOK QOR QOS R89 R9I RHV RIG ROL RPX RRX RSV S16 S27 S37 S3B SAP SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 TEORI TR2 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 X7M YLTOR Z45 ZGI ZMTXR ZOVNA ~EX ~KM 2.D 28- 3O- 5QI A8Z AAUYE ABHQN ABRTQ ABWNU ACUDM ADKNI AEFIE AFEXP AFOHR AFQWF AHAVH AIIXL BBWZM EMB EMOBN GRRUI IQODW KOW MVM NDZJH PJZUB PPXIY R4E S1Z S26 S28 SCLPG SDE SV3 T16 -53 -5E -5G -BR -EM 3V. AAAVM ADINQ CGR CUY CVF ECM EIF GQ6 NPM Z7U Z7V Z7W Z82 Z83 Z87 Z8O Z8P Z8Q Z8V Z8W Z91 Z92 7X8 |
ID | FETCH-LOGICAL-c357t-7ad20e40bceb009b5bbcc77937bdc6ac15ba5496b8377061d9ca24928036d39c3 |
ISSN | 0012-186X |
IngestDate | Tue Aug 05 10:30:21 EDT 2025 Wed Feb 19 01:20:12 EST 2025 Mon Jul 21 09:14:59 EDT 2025 Tue Jul 01 02:04:38 EDT 2025 Thu Apr 24 23:01:11 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Endocrinopathy Human Immunopathology Cytokine Langerhans islet Autoimmune disease B-Vitamins In vitro Necrosis B-Cell Cell death Insulin dependent diabetes Nicotinamide Protection Endocrine pancreas Apoptosis |
Language | English |
License | http://www.springer.com/tdm CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c357t-7ad20e40bceb009b5bbcc77937bdc6ac15ba5496b8377061d9ca24928036d39c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://link.springer.com/content/pdf/10.1007/s001250051113.pdf |
PMID | 10027579 |
PQID | 69584615 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_69584615 pubmed_primary_10027579 pascalfrancis_primary_1737413 crossref_citationtrail_10_1007_s001250051113 crossref_primary_10_1007_s001250051113 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1999-01-01 |
PublicationDateYYYYMMDD | 1999-01-01 |
PublicationDate_xml | – month: 01 year: 1999 text: 1999-01-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany |
PublicationTitle | Diabetologia |
PublicationTitleAlternate | Diabetologia |
PublicationYear | 1999 |
Publisher | Springer |
Publisher_xml | – name: Springer |
SSID | ssj0003546 |
Score | 1.8754497 |
Snippet | Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 55 |
SubjectTerms | Animals Apoptosis - drug effects Apoptosis - physiology Biological and medical sciences Cell Survival - drug effects Cells, Cultured Cytokines - pharmacology Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Humans Hydrogen Peroxide - pharmacology Interferon-gamma - pharmacology Interleukin-1 - pharmacology Islets of Langerhans - cytology Islets of Langerhans - drug effects Islets of Langerhans - pathology Male Medical sciences Necrosis Niacinamide - pharmacology Rats Rats, Wistar Recombinant Proteins - pharmacology Streptozocin - toxicity Tumor Necrosis Factor-alpha - pharmacology |
Title | Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10027579 https://www.proquest.com/docview/69584615 |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgkxASQtwpsOEHxEsXlMROEz_CFFQQ66puk_pW2Y4zIaa0Ii7S-PUcX3Jpy8TlxYrSo6TK9-X4HMfnOwi9ITxSaSx5wMJMBVTCwCglQVkSyiRMSEKaQuGTyWh8QT_Pk3nX7shWl2jxTv78bV3J_6AK5wBXUyX7D8i2F4UTcAz4wggIw_hXGBsY9VfTUr4w9U5WcaH2bfeE0nxoluXrIb-E9L_WQ-nFAa6uA8jE1_bLvzLTpNMZEGs9rJa6M7_Wy28QhLbGfLVcaWPdj2jdlhrrQlsPPz49neWTs42l0umnaf4lz2dn3Tbjwlffsa3Fhmaxse9RoziIMtuNsPWoNN5hjnOPTpHXT7ROCXzHhbtdG6YjGkRn4DIiV6u6KZW9NYW1GwujlECIRG6j_RjSBtPRIp23CXhIfOFW85-95qotpezfbyNGubfiNUBTuj4nNyciNiA5f4Du-0wCv3e0eIhuqeoRunPi90o8Rj_67MANO7BlBzbswJYd2MONd9mBG3YcYeAGBm50xlvcwC03nqCLj_n58TjwXTYCSZJUBykv4lDREF5KcMFMJEJImRrZRFHIEZdRInhC2UhkJE0h-iuY5EZmMoPYpyBMkqdor1pW6jnCCSuVLJOIlKWioqRZFErC4Cgk8EPGB-ioea4L6SXoTSeUq0Urnt2HYYDetuYrp71yk-HBBkidtaPDAL1uQFuA9zRPl1dqua4XI2YC8CgZoGcOy96NzAf9lL34w7Vforvdi_IK7enva3UAcaoWh5Z8MGbH0SHa_5BPprNfdeeZEg |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nicotinamide+protects+human+beta+cells+against+chemically-induced+necrosis%2C+but+not+against+cytokine-induced+apoptosis&rft.jtitle=Diabetologia&rft.au=HOORENS%2C+A&rft.au=PIPELEERS%2C+D&rft.date=1999-01-01&rft.pub=Springer&rft.issn=0012-186X&rft.volume=42&rft.issue=1&rft.spage=55&rft.epage=59&rft_id=info:doi/10.1007%2Fs001250051113&rft.externalDBID=n%2Fa&rft.externalDocID=1737413 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-186X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-186X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-186X&client=summon |